Pembrolizumab combined with neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy followed surgery for locally advanced esophageal squamous cell carcinoma: Protocol for a multi-center, prospective, randomized-controlled, phase III clinical study (Keystone-002)

被引：0

作者：

Jiang, H. ^{[1
]}

Shang, X. ^{[1
]}

Zhang, C. ^{[1
]}

Yue, J. ^{[1
]}

Duan, X. ^{[1
]}

Ma, Z. ^{[1
]}

Chen, C. ^{[1
]}

Zhang, W. ^{[1
,2
]}

Pang, Q. ^{[1
]}

Zhang, W. ^{[1
,2
]}

Liu, L. ^{[2
]}

Ren, X. ^{[2
]}

Meng, B. ^{[3
]}

Zhao, G. ^{[3
]}

Zhang, P. ^{[4
]}

Wei, Y. ^{[5
]}

Ma, Y. ^{[6
]}

Zhang, L. ^{[7
]}

Li, Y. ^{[8
]}

机构：

[1] Tianjin Med Univ, Canc Inst & Hosp, Dept Minimally Invas Esophageal Surg, Tianjin, Peoples R China

[2] Tianjin Med Univ, Canc Inst & Hosp, Dept Immunol, Tianjin, Peoples R China

[3] Tianjin Med Univ, Canc Inst & Hosp, Dept Pathol, Tianjin, Peoples R China

[4] Tianjin Med Univ, Gen Hosp, Dept Thorac Surg, Tianjin, Peoples R China

[5] Qingdao Univ, Affiliated Hosp, Dept Thorac Surg, Qingdao, Peoples R China

[6] Liaoning Canc Hosp, Dept Thorac Surg, Shenyang, Peoples R China

[7] Shandong First Med Univ, Shandong Prov Hosp, Dept Thorac Surg, Jinan, Peoples R China

[8] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Canc Hosp, Dept Thorac Surg Oncol, Beijing, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.10.185

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

166TiP

引用

页码：S1454 / S1455

页数：2

共 50 条

[21] Phase III Randomized Study of Preoperative Versus Postoperative Chemoradiotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Xu, Y.
Chen, Q.
Sun, X.
Liu, J.
Jiang, Y.
Ye, P.
Wei, Q.
Zhou, X.
Mao, W.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S30 - S30
[22] Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)
Shang, Xiaobin
Zhao, Gang
Liang, Fei
Zhang, Chen
Zhang, Weihong
Liu, Liang
Li, Runmei
Duan, Xiaofeng
Ma, Zhao
Yue, Jie
Chen, Chuangui
Meng, Bin
Ren, Xiubao
Jiang, Hongjing
ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (04)
[23] Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.
Li, Yin
Qin, Jianjun
Xue, Liyan
Hao, Anlin
Jiang, Tao
Liu, Shuoyan
Jiang, Hongjing
Kang, Mingqiang
Li, Hecheng
Tian, Hui
Fu, Junke
Ma, Jianqun
Fu, Maoyong
Han, Yongtao
Chen, Longqi
Tan, Lijie
Dai, Tianyang
Liao, Yongde
Zhang, Weiguo
Li, Bin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : LBA244 - LBA244
[24] Neoadjuvant tislelizumab combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Single arm phase II study
Jin, Peng
Gao, Yong Sheng
Fu, Zheng
Yang, Wen Feng
Meng, Xue
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[25] A phase II randomized trial comparing neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in advanced squamous cell carcinoma of the pharynx or larynx
Huang, Pei-Wei
Lin, Chien-Yu
Hsieh, Chia-Hsun
Hsu, Cheng-Lung
Fan, Kang-Hsing
Huang, Shiang-Fu
Liao, Chun-Ta
Ng, Shu-Kung
Yen, Tzu-Chen
Chang, Joseph Tung-Chieh
Wang, Hung-Ming
BIOMEDICAL JOURNAL, 2018, 41 (02) : 129 - 136
[26] Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903)
Hai-Bo Sun
Wen-Qun Xing
Xian-Ben Liu
Yan Zheng
Shu-Jun Yang
Zong-Fei Wang
Shi-Lei Liu
Yu-Feng Ba
Rui-Xiang Zhang
Bao-Xing Liu
Cheng-Cheng Fan
Pei-Nan Chen
Guang-Hui Liang
Yong-Kui Yu
Qi Liu
Hao-Ran Wang
Hao-Miao Li
Zhen-Xuan Li
BMC Cancer, 20
[27] Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903)
Sun, Hai-Bo
Xing, Wen-Qun
Liu, Xian-Ben
Zheng, Yan
Yang, Shu-Jun
Wang, Zong-Fei
Liu, Shi-Lei
Ba, Yu-Feng
Zhang, Rui-Xiang
Liu, Bao-Xing
Fan, Cheng-Cheng
Chen, Pei-Nan
Liang, Guang-Hui
Yu, Yong-Kui
Liu, Qi
Wang, Hao-Ran
Li, Hao-Miao
Li, Zhen-Xuan
BMC CANCER, 2020, 20 (01)
[28] Efficacy and safety of camrelizumab combined with chemotherapy versus chemotherapy alone as preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma: Preliminary results from a multicenter, prospective, randomized controlled study
Zhang, Renquan
Song, De Sheng
Liu, Wei
Yao, Long
Chen, An Guo
Ge, Wei
Hu, Shao Hui
Chen, Jian
Huang, Yun Long
Xun, Jun Rui
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[29] Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery in patients with locally advanced esophageal squamous cell carcinoma who achieved clinical complete response when induction chemoradiation finished: A phase II random
Qian, Dong
Chen, Xi
Shang, Xiaobin
Wang, Yuwen
Tang, Peng
Han, Dong
Jiang, Hongjing
Chen, Chuangui
Zhao, Gang
Zhou, Dejun
Cao, Fuliang
Er, Puchun
Zhang, Wencheng
Li, Xiaoxia
Zhang, Tian
Zhang, Baozhong
Guan, Yong
Wang, Jun
Yuan, Zhiyong
Yu, Zhentao
Wang, Ping
Pang, Qingsong
RADIOTHERAPY AND ONCOLOGY, 2022, 174 : 1 - 7
[30] Safety and feasibility of esophagectomy following neoadjuvant immunotherapy combined with chemotherapy or chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: Analysis of two phase 2 clinical trials
Shen, Dijian
Chen, Runzhe
Ji, Yongling
Chen, Qixun
Chen, Ming
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →